Skip to main content
رجوع
UTHR logo

United Therapeutics Corporation

جودة البيانات: 100%
UTHR
NASDAQ Healthcare Biotechnology
KWD 531.82
▲ KWD 10.60 (2.03%)
القيمة السوقية: 23.31B
نطاق اليوم
KWD 517.63 KWD 536.02
نطاق 52 أسبوعًا
KWD 266.98 KWD 548.12
حجم التداول
539,645
متوسط 50 يوم / 200 يوم
KWD 491.10 / KWD 415.89
الإغلاق السابق
KWD 521.22

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 17.5 0.4
P/B 3.3 2.9
ROE % 19.7 3.9
Net Margin % 41.9 3.8
Rev Growth 5Y % 17.2 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 579.830 +9.0%
Low: KWD 447.000 High: KWD 645.000
مكرر الربحية المستقبلي
17.7
ربحية السهم المستقبلية
KWD 29.411
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
3.3 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 53.130
KWD 46.510 – KWD 59.627
5.8 B 4
FY2029 KWD 46.470
KWD 40.680 – KWD 52.152
5.1 B 4
FY2028 KWD 38.675
KWD 27.430 – KWD 51.063
4.3 B 10

النقاط الرئيسية

Revenue grew 17.22% annually over 5 years — strong growth
ROE of 19.71% — decent returns on equity
Net margin of 41.94% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 1.04B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6.61%

النمو

Revenue Growth (5Y)
17.22%
Revenue (1Y)10.61%
Earnings (1Y)11.68%
FCF Growth (3Y)17.99%

الجودة

Return on Equity
19.71%
ROIC15.77%
Net Margin41.94%
Op. Margin46.89%

الأمان

Debt / Equity
0.00
Current Ratio6.60
Interest Coverage76.54

التقييم

P/E Ratio
17.46
P/B Ratio3.28
EV/EBITDA14.57
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.61% Revenue Growth (3Y) 16.94%
Earnings Growth (1Y) 11.68% Earnings Growth (3Y) 16.42%
Revenue Growth (5Y) 17.22% Earnings Growth (5Y) 29.42%
Profitability
Revenue (TTM) 3.18B Net Income (TTM) 1.33B
ROE 19.71% ROA 16.94%
Gross Margin 87.92% Operating Margin 46.89%
Net Margin 41.94% Free Cash Flow (TTM) 1.04B
ROIC 15.77% FCF Growth (3Y) 17.99%
Safety
Debt / Equity 0.00 Current Ratio 6.60
Interest Coverage 76.54 Dividend Yield 0.00%
Valuation
P/E Ratio 17.46 P/B Ratio 3.28
P/S Ratio 7.32 PEG Ratio 1.16
EV/EBITDA 14.57 Dividend Yield 0.00%
Market Cap 23.31B Enterprise Value 21.75B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.18B 2.88B 2.33B 1.94B 1.69B
Net Income 1.33B 1.20B 984.80M 727.30M 475.80M
EPS (Diluted) 27.86 24.64 19.81 15.00 10.06
Gross Profit 2.80B 2.57B 2.07B 1.79B 1.56B
Operating Income 1.49B 1.38B 1.18B 979.70M 555.90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.88B 7.36B 7.17B 6.04B 5.17B
Total Liabilities 783.80M 920.00M 1.18B 1.25B 1.21B
Shareholders' Equity 7.10B 6.44B 5.98B 4.80B 3.96B
Total Debt 0.0 300.00M 700.00M 800.00M 800.00M
Cash & Equivalents 1.56B 1.70B 1.21B 961.20M 894.80M
Current Assets 3.70B 3.87B 3.55B 3.38B 2.32B
Current Liabilities 560.60M 738.10M 804.40M 343.20M 305.40M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Balanced Risk
#105 of 151
41

النشاط الأخير

دخل Balanced Risk
Mar 24, 2026